Protein Chromatography Resin Patents: Who Leads, Trends 2026
Protein Chromatography Resin Selection Patents: Filing Trends and Who Holds the Ground
Filings have cooled from their 2020 peak. 143 records that year against 84 in 2021 and 66 in 2024, a -21% slide over that three-year span — not a collapse, but a market past its filing surge. Filings rose to a peak of 143 in 2020, then eased to 84 in 2021 and 66 in 2024 — a -21% change over that span. The most recent years are still filling in under publication lag and should be read with that in mind rather than as evidence of a declining field.
- 1REGENERON PHARMACEUTICALS INC4.9%
- 2EMD MILLIPORE CORP2.7%
- 3CYTIVA BIOPROCESS R&D AB2.5%
- 4GENZYME CORP2.3%
- 5CORIXA CORP2.2%
See the full protein chromatography resin selection analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in protein chromatography resin selection?
One assignee leads the ranked list with 188 records, more than double the fifth-place holder’s 83. The top 5 assignees combined hold 14.5% of all 3,831 records in scope, and the top 10 hold 24.4%, so while there is a clear leader, the majority of filing activity is spread across a long tail of 100 ranked companies. No single company controls enough of the claim space to be described as dominant.
Is patent filing in this field growing or slowing down?
Filings peaked at 143 in 2020 and eased to 66 by 2024, a -21% change over that three-year window, which reads as a return to a lower baseline rather than a field in decline. The 2025 and 2026 figures in any trend chart will look lower still simply because publication typically lags filing by around 18 months, not because activity has stopped. The more complete picture is that this is a mature field past its filing surge, still actively defended by its historic leaders.
What technology areas dominate protein chromatography resin patents?
C07K, covering peptide and protein chemistry, appears in 73.5% of the 3,831 records in scope, making it the single largest IPC class by a wide margin. C12N genetic engineering (46.2%) and B01D separation processes (42.1%) follow, with B01J catalysis and process claims at 27.8%. Because most records carry more than one IPC code, these shares add up to well over 100%, and resin engineering claims are typically filed alongside molecule-specific biology claims rather than as standalone process patents.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Protein Chromatography Resin Selection covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.